Composition containing fish eyes, theanine and gamma-aminobutyric acid and capable of alleviating asthenopia

A technology to relieve visual fatigue and aminobutyric acid, which is applied in the field of medicine and health, can solve problems such as inattention, memory loss, and ineffective improvement of local eye symptoms, achieve broad market prospects, and improve the effect of mental and neurological symptoms

Inactive Publication Date: 2018-08-03
成都图径生物科技有限公司
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, the products on the market to improve visual fatigue usually only target blue light damage itself, and have no obvious improvement effect on local eye symptoms, and cannot solve other symptoms caused by different degrees of visual fatigue, such as inattention, memory loss, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing fish eyes, theanine and gamma-aminobutyric acid and capable of alleviating asthenopia
  • Composition containing fish eyes, theanine and gamma-aminobutyric acid and capable of alleviating asthenopia
  • Composition containing fish eyes, theanine and gamma-aminobutyric acid and capable of alleviating asthenopia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1 Manufacture of fish eyeball extracts (with DHA as an index component) such as tuna, tuna, bonito, horse mackerel, tilapia

[0045] Raw material processing: take the fish eye (eyeball tissue) of fresh sea fish, wash it with water, drain it, soak it in 0.05-0.1% citric acid solution for 10-30min, dry it at 40-70°C until the water content is less than 4%, and then Grinding to 100-200 mesh sea fish meal;

[0046] Enzymolysis: add buffer solution to the treated sea fish meal and adjust the pH value to 4-6 with 6mol / L hydrochloric acid, add mass fraction 0.1-1.0%, enzyme activity 3.0×10 4 u / g papain and mass fraction 0.5-1.5%, enzyme activity 1.0×10 4 u / g cellulase, stir and enzymolyze at 40-60°C for 1-2h, then adjust the pH to neutral with 0.5mol / L sodium hydroxide;

[0047] Vacuum extraction: put the obtained marine fish enzymatic hydrolyzate in a vacuum extraction equipment, control the vacuum degree to 85-90KPa, extract at a temperature of 40-60°C for 1-2 hour...

Embodiment 2

[0050] Manufacture of fish eye socket extracts (with DPA, EPA and DHA as index components) such as embodiment 2 tuna, tuna, bonito, horse mackerel, tilapia

[0051] Wash the processed eye sockets of sea fish, add water at a ratio of solid-liquid weight ratio of 1:1-1.2, and then grind it into a slurry to obtain a homogenate; extract the homogenate with an organic solvent for 1-3 times, and mix the organic solvent with the homogenate The ratio of slurry volume is 1:1.2-1.5, collect the extract, and obtain the extract containing DPA, EPA and DHA for future use. The organic solvent refers to petroleum ether or ether; the organic solvent is recovered from the extract to obtain DPA, For the fish oil of EPA and DHA, mix 0.3mol / L sodium methoxide with the same volume of fish oil, fill with nitrogen and stir for 10 minutes at room temperature, adjust the pH value to 7.0-7.2, recover methanol, and obtain methylated fish oil; Molecular distillation of esterified fish oil includes three ...

Embodiment 3

[0052] The preparation of embodiment 3 compositions of the present invention

[0053] Raw material weight ratio: 300-600 parts of fish eye socket tissue pulverization or extract (based on fresh product weight), 300-600 parts of fish eye ball tissue pulverization or extract (based on fresh product weight), theanine 200-600 parts 400 parts, 100-300 parts of γ-aminobutyric acid, 50-200 parts of anthocyanins (or astaxanthin: 4-12 parts and or 1-200 parts of proanthocyanidins), (3R,3'R)-dihydroxy- 1-5 parts of β-carotene, 5-15 parts of lutein and / or lutein ester.

[0054] Preparation:

[0055] 1. The pulverized fish eye socket tissue or extract (by weight of fresh product), the pulverized product or extract of fish eyeball tissue (calculated by fresh product weight), theanine, γ-aminobutyric acid, and cyanine according to the weight ratio (or astaxanthin and or proanthocyanidin), (3R,3'R)-dihydroxy-β-carotene, lutein ester are mixed evenly, then added to the syrup and stirred eve...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a composition containing fish eyes, theanine and gamma-aminobutyric acid and capable of alleviating asthenopia, belongs to the field of medicine health, and provides a composition capable of alleviating asthenopia. The active components of the composition comprise fish eyeball tissues or an extract thereof, fish eye socket tissues and an extract thereof, the theanine and the gamma-aminobutyric acid. Test results in crowds prove that the composition has effect on eye local symptoms of asthenopia, can obviously improve the neurosis symptoms caused by asthenopia of different degrees, such as unconcentrated attention, and reduced memory, is notable in effect of alleviating asthenopia and has broad market development prospect.

Description

technical field [0001] The invention relates to a composition for relieving visual fatigue containing fish eyes, theanine and gamma-aminobutyric acid, which belongs to the field of medicine and health. Background technique [0002] Visual fatigue, also known as eye fatigue, is a syndrome based on the subjective symptoms of the patient's eyes, eye or systemic organic factors and mental (psychological) factors. It is not an independent eye disease, so it is often called eye fatigue syndrome. (Refer to: 1. Li Fengming. Chinese Ophthalmology [M]. Beijing: People's Health Publishing House, 2006, 7-8; 2. Qu Hongying et al. Research progress on etiology and treatment of visual fatigue [J]. Chinese Medicine Ophthalmology Journal, 2003, 14(1): 59-61). Mild visual fatigue will cause eye symptoms such as eye soreness and swelling after using the eyes, and will recover soon after rest; moderate visual fatigue will have obvious eye symptoms, which will affect study and work; severe visu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A23L33/10A23L33/175A23L33/105A23L17/00A23L17/20A23L2/38A23L21/10A23G3/36A23G3/48A21D13/06A21D2/36A61K35/60A61P27/02A61K31/198A61K31/197A61K31/685A61K31/122A61K31/352A61K31/047A61K31/015
CPCA61P27/02A21D2/36A21D13/06A23G3/36A23G3/48A23L2/38A23L17/00A23L17/20A23L21/10A23L33/10A23L33/105A23L33/175A61K31/015A61K31/047A61K31/122A61K31/197A61K31/198A61K31/352A61K35/60A23V2002/00A23V2200/30A23V2200/322A23V2250/0646A23V2250/038A23V2250/2104A23V2250/2042A61K2300/00
Inventor 魏巍
Owner 成都图径生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap